BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,550,000 shares, an increase of 9.4% from the December 15th total of 2,330,000 shares. Based on an average daily trading volume, of 806,600 shares, the days-to-cover ratio is currently 3.2 days.

BioNTech Trading Down 0.7 %

Shares of BNTX opened at $111.93 on Monday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $26.83 billion, a P/E ratio of -53.30 and a beta of 0.18. The stock’s fifty day simple moving average is $114.69 and its 200 day simple moving average is $104.76. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period last year, the company posted $0.73 earnings per share. The firm’s revenue was up 38.9% compared to the same quarter last year. On average, equities research analysts forecast that BioNTech will post -3.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BNTX. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 target price on the stock. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Wells Fargo & Company initiated coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price on the stock. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Planning Capital Management Corp raised its position in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. raised its position in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the period. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new position in shares of BioNTech in the third quarter worth about $210,000. Finally, Probity Advisors Inc. acquired a new position in shares of BioNTech in the third quarter worth about $216,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.